Biocon (BIOCON) Q3 2026 earnings summary

Executive summary

• Completed strategic merger and integration of Biocon Biologics, creating a $5.5B global biopharma platform with a unified structure and strengthened balance sheet.

• Focused on high-growth biosimilars, insulins, GLP-1 peptides, and oncology, with a robust pipeline and global reach.

• Transitioned to sustainable growth, margin expansion, and cash flow generation, with major CapEx cycle largely complete.

• Board approved financial results and in-principle acquisition of remaining BBL equity, moving towards full integration.

• Strengthened balance sheet through major capital raises, debt refinancing, and early redemption of NCDs and commercial papers.

Financial highlights

• Q3 FY26 operating revenue rose 9% YoY to INR 4,173 crore (₹41,730 million), led by biosimilars and generics; all segments showed YoY growth.

• Core EBITDA grew 21% YoY to INR 1,221 crore (29% margin); reported EBITDA at INR 951 crore (22% margin).

• Net profit before exceptional items at INR 124 crore, up 844% YoY; reported net profit at INR 144 crore, up 475% YoY; consolidated net loss of Rs. 518 million due to exceptional items.

• Nine-month FY26 operating revenue and EBITDA up 14% and 24% YoY, respectively; net profit at INR 260 crore.

• R&D spend at ₹249 crore, 8% of revenue (excluding Syngene).

Outlook and guidance

• Focus on sustainable growth, margin expansion, and improving ROCE, with CapEx to moderate and future investments mainly for maintenance.

• Board prioritizes full BBL integration and capital structure optimization; recent capital raises and debt refinancing to enhance liquidity.